GSK, Shenzhen Neptunus Collaborate To Develop, Manufacture Influenza Vaccines

Published: 09-Jun-2009

New vaccines to benefit public health in China and neighbouring territories

GlaxoSmithKline has announced that it has entered into an agreement to form a new joint venture with Shenzhen Neptunus Interlong. The latter is focused on developing and manufacturing influenza vaccines for the Chinese market.

According to this agreement, the alliance will develop and manufacture influenza vaccines for China, Hong Kong and Macau. This will include vaccines for seasonal, pre-pandemic and pandemic influenza. It is expected that these vaccines will be available over the next few years.

Jean Stephenne, President and General Manager, GlaxoSmithKline, said: “This new alliance enables GSK to build new vaccines capability in a critical emerging market such as China. The new Joint Venture will combine the potential of GSK’s adjuvant technology and expertise in vaccine development together with the extensive experience of Shenzhen Neptunus in the Chinese vaccines market. Together we will gain access to specific local influenza antigens and make available new vaccines to benefit public health in China and neighbouring territories.”

Tell your friend about this article